Monocyte/macrophages as effector cells in cancer immunotherapy

Transfusion Science

Volumn 18, Issue 2, 1997, Pages 243-250

  Oberling, F ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD COMPONENT THERAPY; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVATION; CELL COUNT; CELL SEPARATION; CELL TRANSFER; CLINICAL PROTOCOL; CLINICAL STUDY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; IN VITRO STUDY; INFUSION; KILLER CELL; LEUKOCYTE; LYMPHOCYTE CULTURE; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; PHAGOCYTOSIS; TUMOR CELL;

HUMANS; IMMUNOTHERAPY; MACROPHAGES; MONOCYTES; NEOPLASMS; TISSUE THERAPY;

EID: 0030694495     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(97)00017-9     Document Type: Article

References (40)

1. Hibbs JB, Jr: Heterocytolysis by macrophages activated by Bacillus Calmette Guerin: Lysosome exocytosis into tumour cells. Science 1974; 184:468-471.
2. Bucana CD, Hoyer LL, Hobbs B: Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages in to the cytoplasm of tumour target cells. Cancer Res 1976; 36:4444-4458.
3. Bucana CD, Hoyer LL, Schroit AJ: Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am Journal Path 1983; 112:101-111.
4. Adams DO, Marino PA: Evidence for multistep mechanism of cytolysis by BCG-activated macrophages. The interrelationship between the capacity for cytolysis, target binding and secretion of cytolytic factor. J Immunol 1981; 126:981-987.
5. Somers SD, Whisnant CC, Adams DO: Quantification of the strength of cell cell adhesion: The capture of tumour cells by activated murine macrophages proceeds through two distinct stages. J Immunol 1986; 136:1490-1496.
6. Fidler IJ, Kleinerman ES: Lymphokine-activated human blood monocytes destroy tumour cells but not normal cells under cocultivation conditions. J Clin Oncol 1984; 2:937-943.
7. Fogler WE, Fidler IJ: Nonselective destruction of murine neoplastic cells by syngenic tumouricidal macrophages. Cancer Res 1985; 45:14-18.
8. Pak CC, Fidler IJ: Activated macrophages distinguish undifferentiated tumourigenic from differentiated non tumourigenic murine erythroleukemia cells. Differentiation 1989; 41:49-55.
9. Brunda MJ, Wiltrout RH, Holden HT, Varesio L: Selective inhibition by monosaccharides of tumour cell cytotoxicity mediated by mouse macrophages, macrophage like cell lines, and natural killer cells. Int J Cancer 1983; 31:373-379.
10. Munn DH, Chenng NK: Antibody independent phagocytosis of tumour cells by human monocyte-derived macrophages cultured in recombinant macrophage colony stimulating factor. Cancer Immunol Immunother 1995; 41:46-52.
11. Ely P, Wallace PK, Givan AL: Bispecific armed, interferon primed macrophage mediated phagocytosis of malignant non Hodgkin's lymphoma. Blood 1996; 87:3813-3821.
12. Nathan CF: Secretory products of macrophages. J Clin Invest 1987; 78:319-330.
13. Allison AC: Mode of action of immunological adjuvants. F Reticuloendothel Soc 1979; 26:619-630.
14. Lederer E: Synthetic immunostimulants derived from the bacterial cell wall. J Med Chem 1980; 23:819-825.
15. Ogler, WE, Fidler, IJ: Modulation of the immune response by muramyl dipeptide, in Chirigos MA and Fenichet RL (eds): Immune Modulation Agents and Their Mechanisms. New York, Marcel Dekker, 1984, 499-512.
16. Fidler IJ: Macrophages and metastasis. A biological approach to cancer therapy: presidential address. Cancer Res 1985; 45:4714-4726.
17. Sone S, Utsugi T, Tandon P, Ogawara M: A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the anticancer state. Cancer Immunol Immunother 1986; 22:191-196.
18. Fidler IJ, Murray JL, Kleinerman EJ: Systemic activation of macrophages by liposome containing immunomodulators, in Hellman S, De Vita Jr VT, Rosenberg SA (eds): Biologic Therapy of Cancer: Principles and Practice. Philadelphia, J.B. Lippincott Co, 1991, 730-742.
19. Murray JL, Kleinerman ES, Tatom JR: A pilot phase I trial of liposomal N-acutyl muramyl L-alanyl Disoglutaminyl L-alanyl phosphatiolyl ethanolamine (MT-PPE, CGP, 19835 A) in cancer patients, in Lopez Berestein G, Fidler IJ (eds), Liposomes in the Therapy of Infectious Diseases and Cancer. New York, Alan R. Liss, 1989, 329-342.
20. Hwang JK: Liposome pharmacokinetics, in Ostro MJ (ed): Liposomes from Biophysics to Therapeutics. New York, Marcel Dekker, 1987, 109-156.
21. Schroit AJ, Galligioni E, Fidler IJ: Factors influencing the in situ activation of macrophages by liposomes containing muramyl dipeptide. Biol Cell 1983; 47:87-94.
22. Poste G, Kirsh R, Fidler IJ: Cell surface receptors for lymphokines. Cell Immunol. 1979; 44:71-88.
23. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ: Activation or suppression of the tumouricidal properties of monocytes from cancer patients following treatment with human recombinant-interferon. Cancer Res 1986; 46:5401-5405.
24. Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazumder A: Activation of tumouricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 1985; 44:994-998.
25. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY: Induction of macrophage tumouricidal activity by granulocyte macrophage colony stimulating factor. Science 1986; 232:506-507.
26. Williams MA, Kelsey SM, Collins PW, Gutteridge ChN, Newland AC: Administration of rHu GM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high dose chemotherapy. Brit J Haematol 1995; 90:31-40.
27. Wiltschke Ch, Krainer M, Wagner A, Linkesch W, Zielinski ChC: Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 1995; 23:402-406.
28. Ralph R, Nakoinz I: Stimulation of macrophage tumouricidal activity by the growth and differentiation factor CSF-1. Cell Immunol 1987; 105:270-279.
29. Munn DH, Cheung NKV: Antibody dependent antitumour cytotoxicity by human monocytes cultured with recombinant macrophage colony stimulating factor. Induction of efficient antibody mediated antitumour cytotoxicity not detected by isotope relase assays. J Exp Med 1989; 170:511-526.
30. Munn DH, Cheung NKV: Phagocytosis of tumour cells by human monocytes cultured in recombinant macrophage colony stimulating factor. J Exp Med 1990; 172:231-237.
31. Bajorin DF, Cheung NKV, Houghton AN: Macrophage colony stimulating factor: Biological effect and potential application for cancer therapy. Semin Hematol 1991; 28:42-48.
32. Bukowski RM, Budd GT, Gibbons JA: Phase I trial of subcutaneous recombinant macrophage colony stimulating factor: Clinical and immunomodulatory effects. J Clin Oncol 1994; 12:97-106.
33. Fidler, IJ: Immunomodulation of macrophage for cancer and antiviral therapy, in Tomlinson E and Davis JS (eds): Site Specific Drug Delivery. New York, Wiley and Sons, 1986, 111-134.
34. Faradji A, Bohbot A, Schmitt-Goguel M, et al.: Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients J Immunol Meth 1994; 174:297-309
35. Vincent Fl, Eischen A, Bergerat JP, Faradji A, Bohbot A, Oberling F: Human blood derived macrophages: Differentiation in vitro of a large quantity of cells in serum free medium. Exp Hematol 1992; 20:17-23.
36. Eischen A, Vincent Fl, Bergerat JP, et al.: Long term culture of human monocytes in vitro. Impact of GM-CSF on survival and differentiation. J Immunol Meth 1991; 143:203-221.
37. Dumont S, Hartmann D, Poindron P, Oberling F, Faradji A, Bartholeyns J: Control of the antitumoural activity of human macrophages produced in large amounts in view of adoptive transfer. Eur J Cancer Clin Oncol 1988; 24:1691-1698.
38. Faradji A, Bohbot A, Frost H, et al.: Phase I study of liposomal MTP-PE activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 1991; 9:1251-1260.
39. Faradji A, Bohbot A, Schmitt-Goguel M: Phase I trial of intravenous infusion of ex vivo activated autologous blood derived macrophages in patients with non small cell lung cancer: Toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991; 33:319-326.
40. Dufour P, Faradji A, Bohbot A, et al.: Intraperitoneal adoptive immunotherapy by liposomal MTP-PE activated autologous monocytes as a treatment for peritoneal mesothelioma: A case report. Reg Cancer Treat 1993; 2:83-85.